A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study

Chemotherapy is a common treatment for advanced hepatocellular carcinoma, but the effect is not satisfactory. The study aimed to retrospectively evaluate the effects of adding all-trans-retinoic acid (ATRA) to infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) for advanced hepatocellular...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2022-10, Vol.135 (19), p.2338-2343
Main Authors: Sun, Juxian, Liu, Chang, Shi, Jie, Wang, Nanya, Jiang, Dafeng, Mao, Feifei, Gu, Jingwen, Zhou, Liping, Shen, Li, Lau, Wan Yee, Cheng, Shuqun
Format: Article
Language:English
Subjects:
Ablation
Age
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
Carcinoma, Hepatocellular - drug therapy
Cardiovascular disease
Chemotherapy
Disease Progression
Fluorouracil - adverse effects
Hospitals
Humans
Leucovorin - adverse effects
Leukemia
Liver cancer
Liver Neoplasms - drug therapy
Magnetic resonance imaging
Medical prognosis
Metastasis
Original
Oxaliplatin - therapeutic use
Retrospective Studies
Thrombosis
Tretinoin - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemotherapy is a common treatment for advanced hepatocellular carcinoma, but the effect is not satisfactory. The study aimed to retrospectively evaluate the effects of adding all-trans-retinoic acid (ATRA) to infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) for advanced hepatocellular carcinoma (HCC). We extracted the data of patients with advanced HCC who underwent systemic chemotherapy using FOLFOX4 or ATRA plus FOLFOX4 at the Eastern Hepatobiliary Surgery Hospital, First Hospital of Jilin University, and Zhejiang Sian International Hospital and retrospectively compared for overall survival. The Cox proportional hazards model was used to calculate the hazard ratios for overall survival and disease progression after controlling for age, sex, and disease stage. From July 2013 to July 2018, 111 patients with HCC were included in this study. The median survival duration was 14.8 months in the ATRA plus FOLFOX4 group and 8.2 months in the FOLFOX4 only group ( P  
ISSN:0366-6999
2542-5641
DOI:10.1097/CM9.0000000000001952